Metoclopramide

證據等級: L5

預測適應症: 5 個

Metoclopramide: From Gastroparesis & Nausea to Gastric Ulcer

One-Sentence Summary

Metoclopramide is a well-established prokinetic and antiemetic agent, primarily used clinically to treat nausea, vomiting, and delayed gastric emptying (gastroparesis). The TxGNN model predicts it may be effective for Gastric Ulcer, with 2 clinical trials and 20 publications currently available to support this direction — though the majority of evidence is indirect, addressing metoclopramide’s prokinetic properties rather than direct ulcer healing.

Quick Overview

Item	Content
Original Indication	Gastroparesis, nausea, and vomiting (prokinetic / antiemetic)
Predicted New Indication	Gastric Ulcer
TxGNN Prediction Score	99.93%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not formally documented in this Evidence Pack. Based on pharmacological evidence embedded in the supporting literature, Metoclopramide is a dopamine D2 receptor antagonist and serotonin 5-HT4 receptor agonist. Through these dual actions it accelerates gastric emptying, enhances antroduodenal peristaltic coordination, raises lower esophageal sphincter pressure, and reduces bile reflux into the stomach — collectively creating a less hostile mucosal environment.

Gastric ulcer pathophysiology involves an imbalance between aggressive factors (gastric acid, bile reflux, Helicobacter pylori) and mucosal defense mechanisms. Metoclopramide’s prokinetic effects may reduce the duration of acid–mucosa contact and limit bile-induced injury. Animal studies have demonstrated ulcer-protective effects in aspirin-induced and pylorus-ligated models without altering gastric acid secretion, suggesting the protective mechanism is motility-mediated rather than secretory (PMID: 2730234; PMID: 6436177).

That said, it must be clearly noted that Metoclopramide has no direct anti-ulcer mechanism. It neither inhibits acid secretion nor eradicates H. pylori, which is responsible for 70–80% of gastric ulcers. The high TxGNN score likely reflects knowledge graph proximity between Metoclopramide and upper GI disease nodes. The most clinically plausible role is adjunctive therapy in the subgroup of ulcer patients who also have gastroparesis — not as a standalone ulcer treatment. Clinical translation evidence remains thin.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05746377	Phase 4	Unknown	60	Double-blind RCT evaluating IV metoclopramide as pre-endoscopy premedication in upper GI bleeding (including ulcer bleeds); primary endpoints are the need for repeat endoscopy and quality of gastric wall visualization during the procedure
NCT03747107	N/A	Completed	19	Pharmacist-led quality improvement programme (P-DQIP) in Scottish primary care; metoclopramide is not the primary intervention and gastric ulcer healing is not an endpoint — low direct relevance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38059896	2024	RCT	Am J Gastroenterology	Most recent double-blind RCT evaluating IV metoclopramide for gastric visualization in patients with active upper GI bleeding; highest methodological quality in this evidence set
2730234	1989	Animal Study	Arch Int Pharmacodyn Ther	Metoclopramide (20–50 mg/kg) produced ulcer-protective effects in aspirin-induced and pylorus-ligated rat models; efficacy comparable to ranitidine against aspirin-induced ulcers
6436177	1984	Animal Study	Indian J Physiol Pharmacol	Metoclopramide protected guinea pigs against all three experimental gastric ulcer models without affecting acid secretion; mechanism attributed to improved gastric drainage and prevention of pyloric reflux
16807979	2006	RCT (perioperative)	Yonsei Med J	Prospective double-blind RCT (N=40); IV metoclopramide + ranitidine significantly reduced preoperative gastric volume and acidity versus placebo in laparoscopic gynecologic surgery patients
4779253	1973	Clinical Study	Curr Med Res Opin	Assessed metoclopramide’s effect on bile reflux in gastric ulcer patients alongside smoking and carbenoxolone; bile reflux reduction is a plausible mucosal protective mechanism
28652516	2017	Animal Study	J Smooth Muscle Res	Prokinetic drugs including metoclopramide improved gastric emptying after acetic acid-induced ulcers in rats; drug response varied by ulcer anatomical position
6336644	1983	Narrative Review	Ann Intern Med	Comprehensive pharmacology review; describes metoclopramide’s GI smooth muscle stimulatory effects via D2 antagonism and augmented acetylcholine release
775822	1976	Clinical Report	ZFA Zeitschrift Allgemeinmed	Early clinical report on metoclopramide in gastric and duodenal ulcer therapy
19225	1977	Narrative Review	Drugs	Review of pharmacological options for gastric and duodenal ulcer treatment; includes discussion of metoclopramide’s adjunctive role
8095331	1993	Clinical Review	Postgrad Med	Strategies for refractory peptic lesions; notes prokinetics as potential adjuncts when standard H2-blocker regimens fail

India Market Information

Metoclopramide currently has no registered products in the CDSCO database. Market status is recorded as Not Marketed, with zero authorizations on file. There is no local regulatory reference product or approved labelling available for this jurisdiction.

Safety Considerations

Drug Interactions: Metoclopramide has 670 documented drug interactions. The most clinically significant interactions identified in this Evidence Pack are summarised below:

Severity	Interacting Drugs
Major	Tramadol, Amisulpride
Moderate	Fentanyl, Codeine, Dihydrocodeine, Alfentanil, Alprazolam, Amitriptyline, Amantadine, Ethanol, Cetirizine, Chlorpheniramine, Abiraterone, Amifampridine, Amobarbital, Lidocaine (topical), Phenyltoloxamine, Tetracaine (ophthalmic), Dichloralphenazone
Minor	Acetaminophen

Note: Formal key warnings and contraindications data were not available in this Evidence Pack. Please refer to the official prescribing information / package insert for a complete safety profile before any clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a very high TxGNN prediction score (99.93%), the clinical evidence base for Metoclopramide specifically targeting gastric ulcer healing is insufficient to justify advancement. Neither registered trial uses ulcer healing as a primary endpoint, and the supporting literature consists primarily of animal studies, older narrative reviews, and perioperative pharmacology data from unrelated surgical settings. More importantly, Metoclopramide lacks the direct anti-ulcer mechanisms — acid suppression or H. pylori eradication — that underpin all current guideline-recommended regimens. Its best-case role is narrowly adjunctive in a subgroup of ulcer patients with concurrent gastroparesis, and this hypothesis has not been formally tested.

To proceed, the following is needed:

Obtain the official package insert or CDSCO-equivalent product labelling to document formal warnings and contraindications
Retrieve complete MOA documentation from DrugBank (DB01233) to fill the current data gap
Conduct a systematic review targeting Metoclopramide as adjunctive therapy specifically in gastroparesis-complicated gastric ulcer patients
Design a prospective clinical study with ulcer healing rate and symptom resolution as co-primary endpoints in this defined subgroup
Assess the regulatory pathway for India market entry, including the feasibility of a bridging submission given the current zero-registration status
Evaluate whether combination with standard PPI ± H. pylori eradication therapy offers measurable benefit over PPI alone in patients with delayed gastric emptying
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.